<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32414179</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2218-273X</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>May</Month><Day>13</Day></PubDate></JournalIssue><Title>Biomolecules</Title><ISOAbbreviation>Biomolecules</ISOAbbreviation></Journal><ArticleTitle>Peroxisome Proliferator Activator Receptor Gamma Coactivator-1&#x3b1; Overexpression in Amyotrophic Lateral Sclerosis: A Tale of Two Transgenics.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">760</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biom10050760</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder manifesting with upper and lower neuron loss, leading to impairments in voluntary muscle function and atrophy. Mitochondrial dysfunction in metabolism and morphology have been implicated in the pathogenesis of ALS, including atypical oxidative metabolism, reduced mitochondrial respiration in muscle, and protein aggregates in the mitochondrial outer membrane. Peroxisome proliferator-activated receptor &#x3b3; coactivator-1&#x3b1; (PGC-1&#x3b1;) plays an essential role in the regulation of mitochondrial biogenesis, the process by which existing mitochondria grow and divide. PGC-1&#x3b1; has been previously reported to be downregulated in the spinal cord of individuals with ALS. Towards targeting PGC-1&#x3b1; as a therapeutic mechanism, we have previously reported improved motor function and survival in the SOD1<sup>G93A</sup> mouse model of ALS by neuron-specific over-expression of PGC-1&#x3b1; under a neuron-specific enolase (NSE) promoter. As pharmacological intervention targeting PGC-1&#x3b1; would result in whole-body upregulation of this transcriptional co-activator, in the current study we investigated whether global expression of PGC-1&#x3b1; is beneficial in a SOD1<sup>G93A</sup> mouse model, by generating transgenic mice with PGC-1&#x3b1; transgene expression driven by an actin promoter. Actin-PGC-1&#x3b1; expression levels were assayed and confirmed in spinal cord, brain, muscle, liver, kidney, and spleen. To determine the therapeutic effects of global expression of PGC-1&#x3b1;, wild-type, actin-PGC-1&#x3b1;, SOD1<sup>G93A</sup>, and actin-PGC-1&#x3b1;/SOD1<sup>G93A</sup> animals were monitored for weight loss, motor performance by accelerating rotarod test, and survival. Overexpression of actin-PGC-1&#x3b1; did not confer significant improvement in these assessed outcomes. A potential explanation for this difference is that the actin promoter may not induce levels of PGC-1&#x3b1; relevant to disease pathophysiology in the cells that are specifically relevant to the pathogenesis of ALS. This evidence strongly supports future therapeutic approaches that target PGC-1&#x3b1; primarily in neurons.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Varghese</LastName><ForeName>Merina</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-1517-3903</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trageser</LastName><ForeName>Kyle J</ForeName><Initials>KJ</Initials><Identifier Source="ORCID">0000-0001-9161-0178</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasinetti</LastName><ForeName>Giulio M</ForeName><Initials>GM</Initials><Identifier Source="ORCID">0000-0002-1524-5196</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Geriatric Research, Education and Clinical Center, James J. Peters Veterans Affairs Medical Center, Bronx, New York, NY 10468, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AT008661</GrantID><Acronym>AT</Acronym><Agency>NCCIH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>IK6 BX003785</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomolecules</MedlineTA><NlmUniqueID>101596414</NlmUniqueID><ISSNLinking>2218-273X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000199">Actins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071248">Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000199" MajorTopicYN="N">Actins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009132" MajorTopicYN="N">Muscles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071248" MajorTopicYN="N">Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="Y">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011401" MajorTopicYN="N">Promoter Regions, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013154" MajorTopicYN="N">Spleen</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019076" MajorTopicYN="Y">Transgenes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="Y">Up-Regulation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">mitochondrial biogenesis</Keyword><Keyword MajorTopicYN="N">motor function</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">tissue-specific expression</Keyword></KeywordList><CoiStatement>No conflicts of interest exist for any of the authors.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>4</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32414179</ArticleId><ArticleId IdType="pmc">PMC7277592</ArticleId><ArticleId IdType="doi">10.3390/biom10050760</ArticleId><ArticleId IdType="pii">biom10050760</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Renton A.E., Chi&#xf2; A., Traynor B.J. State of play in amyotrophic lateral sclerosis genetics. Nat. Neurosci. 2014;17:17&#x2013;23. doi: 10.1038/nn.3584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3584</ArticleId><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi P., Gal J., Kwinter D.M., Liu X., Zhu H. Mitochondrial dysfunction in amyotrophic lateral sclerosis. Biochimica et Biophysica Acta&#x2014;Mol. Basis Dis. 2010;1802:45&#x2013;51. doi: 10.1016/j.bbadis.2009.08.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2009.08.012</ArticleId><ArticleId IdType="pmc">PMC2790551</ArticleId><ArticleId IdType="pubmed">19715760</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowling A.C., Schulz J.B., Brown R.H., Beal M.F. Superoxide Dismutase Activity, Oxidative Damage, and Mitochondrial Energy Metabolism in Familial and Sporadic Amyotrophic Lateral Sclerosis. J. Neurochem. 1993;61:2322&#x2013;2325. doi: 10.1111/j.1471-4159.1993.tb07478.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.1993.tb07478.x</ArticleId><ArticleId IdType="pubmed">8245985</ArticleId></ArticleIdList></Reference><Reference><Citation>Browne S.E., Bowling A.C., Baik M.J., Gurney M., Brown R.H., Jr., Beal M.F. Metabolic Dysfunction in Familial, but Not Sporadic, Amyotrophic Lateral Sclerosis. J. Neurochem. 2002;71:281&#x2013;287. doi: 10.1046/j.1471-4159.1998.71010281.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1998.71010281.x</ArticleId><ArticleId IdType="pubmed">9648876</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Lillo C., Jonsson P.A., Velde C.V., Ward C.M., Miller T.M., Subramaniam J.R., Rothstein J.D., Marklund S., Andersen P.M., et al. Toxicity of familial ALS-linked SOD1 mutants from selective recruitment to spinal mitochondria. Neuron. 2004;43:5&#x2013;17. doi: 10.1016/j.neuron.2004.06.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2004.06.016</ArticleId><ArticleId IdType="pubmed">15233913</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattiazzi M., D&#x2019;Aurelio M., Gajewski C.D., Martushova K., Kiaei M., Beal M.F., Manfredi G. Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice. J. Biol. Chem. 2002;277:29626&#x2013;29633. doi: 10.1074/jbc.M203065200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M203065200</ArticleId><ArticleId IdType="pubmed">12050154</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkinezos I.G., Bacman S.R., Hernandez D., Oca-Cossio J., Arias L.J., Perez-Pinzon M.A., Bradley W.G., Moraes C.T. Cytochrome c association with the inner mitochondrial membrane is impaired in the CNS of G93A-SOD1 mice. J. Neurosci. 2005;25:164&#x2013;172. doi: 10.1523/JNEUROSCI.3829-04.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3829-04.2005</ArticleId><ArticleId IdType="pmc">PMC6725219</ArticleId><ArticleId IdType="pubmed">15634778</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W., Song Y., Kincaid B., Bossy B., Bossy-Wetzel E. Mutant SOD1G93A triggers mitochondrial fragmentation in spinal cord motor neurons: Neuroprotection by SIRT3 and PGC-1&#x3b1;. Neurobiol. Dis. 2013;51:72&#x2013;81. doi: 10.1016/j.nbd.2012.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2012.07.004</ArticleId><ArticleId IdType="pmc">PMC3992938</ArticleId><ArticleId IdType="pubmed">22819776</ArticleId></ArticleIdList></Reference><Reference><Citation>Dal Canto M.C., Gurney M.E. Development of central nervous system pathology in a murine transgenic model of human amyotrophic lateral sclerosis. Am. J. Pathol. 1994;145:1271&#x2013;1279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1887498</ArticleId><ArticleId IdType="pubmed">7992831</ArticleId></ArticleIdList></Reference><Reference><Citation>Onesto E., Colombrita C., Gumina V., Borghi M.O., Dusi S., Doretti A., Fagiolari G., Invernizzi F., Moggio M., Tiranti V., et al. Gene-specific mitochondria dysfunctions in human TARDBP and C9ORF72 fibroblasts. Acta Neuropathol. Commun. 2016;4:47. doi: 10.1186/s40478-016-0316-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0316-5</ArticleId><ArticleId IdType="pmc">PMC4858818</ArticleId><ArticleId IdType="pubmed">27151080</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiedemann F.R., Winkley K., Kuznetsov A.V., Bartels C., Vielhaber S., Feistner H., Kunz W.S. Impairment of mitochondrial function in skeletal muscle of patients with amyotrophic lateral sclerosis. J. Neurol. Sci. 1998;156:65&#x2013;72. doi: 10.1016/S0022-510X(98)00008-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(98)00008-2</ArticleId><ArticleId IdType="pubmed">9559989</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen S.P., Duffy L.M., Shaw P.J., Grierson A.J. Altered age-related changes in bioenergetic properties and mitochondrial morphology in fibroblasts from sporadic amyotrophic lateral sclerosis patients. Neurobiol. Aging. 2015;36:2893&#x2013;2903. doi: 10.1016/j.neurobiolaging.2015.07.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.07.013</ArticleId><ArticleId IdType="pubmed">26344876</ArticleId></ArticleIdList></Reference><Reference><Citation>Konrad C., Kawamata H., Bredvik K., Arreguin A., Cajamarca S.A., Hupf J.C., Ravits J., Miller T.M., Maragakis N.J., Hales C.M., et al. Fibroblast bioenergetics to classify amyotrophic lateral sclerosis patients. Mol. Neurodegener. 2017;12:76. doi: 10.1186/s13024-017-0217-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0217-5</ArticleId><ArticleId IdType="pmc">PMC5655870</ArticleId><ArticleId IdType="pubmed">29065921</ArticleId></ArticleIdList></Reference><Reference><Citation>Codron P., Cassereau J., Vourc&#x2019;H P., Veyrat-Durebex C., Blasco H., Kane S., Procaccio V., Letournel F., Verny C., Lenaers G., et al. Primary fibroblasts derived from sporadic amyotrophic lateral sclerosis patients do not show ALS cytological lesions. Amyotroph. Lateral Scler. Front. Degener. 2018;19:446&#x2013;456. doi: 10.1080/21678421.2018.1431787.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1431787</ArticleId><ArticleId IdType="pubmed">29382228</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith E.F., Shaw P.J., De Vos K.J. The role of mitochondria in amyotrophic lateral sclerosis. Neurosci. Lett. 2019;710:132933. doi: 10.1016/j.neulet.2017.06.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2017.06.052</ArticleId><ArticleId IdType="pubmed">28669745</ArticleId></ArticleIdList></Reference><Reference><Citation>Villena J.A. New insights into PGC-1 coactivators: Redefining their role in the regulation of mitochondrial function and beyond. FEBS J. 2015;282:647&#x2013;672. doi: 10.1111/febs.13175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.13175</ArticleId><ArticleId IdType="pubmed">25495651</ArticleId></ArticleIdList></Reference><Reference><Citation>Thau N., Knippenberg S., Korner S., Rath K.J., Dengler R., Petri S. Decreased mRNA expression of PGC-1&#x3b1; and PGC-1&#x3b1;regulated factors in the SOD1G93A ALS mouse model and in human sporadic ALS. J. Neuropathol. Exp. Neurol. 2012;71:1064&#x2013;1074. doi: 10.1097/NEN.0b013e318275df4b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e318275df4b</ArticleId><ArticleId IdType="pubmed">23147503</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell A., Wada S., Vergani L., Hock M.B., Lamon S., L&#xe9;ger B., Ushida T., Cartoni R., Wadley G.D., Hespel P., et al. Disruption of skeletal muscle mitochondrial network genes and miRNAs in amyotrophic lateral sclerosis. Neurobiol. Dis. 2013;49:107&#x2013;117. doi: 10.1016/j.nbd.2012.08.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2012.08.015</ArticleId><ArticleId IdType="pubmed">22975021</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang H., Ward W.F., Jang Y.C., Bhattacharya A., Bokov A.F., Jernigan A., Richardson A., Van Remmen H. PGC-1&#x3b1; protects neurons and alters disease progression in an amyotrophic lateral sclerosis mouse model. Muscle Nerve. 2011;44:947&#x2013;956. doi: 10.1002/mus.22217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.22217</ArticleId><ArticleId IdType="pubmed">22102466</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W., Varghese M., Yemul S., Pan Y., Cheng A., Marano P., Hassan S., Vempati P., Chen F., Qian X., et al. Peroxisome proliferator activator receptor gamma coactivator-1alpha (PGC-1&#x3b1;) improves motor performance and survival in a mouse model of amyotrophic lateral sclerosis. Mol. Neurodegener. 2011;6:51. doi: 10.1186/1750-1326-6-51.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-6-51</ArticleId><ArticleId IdType="pmc">PMC3156746</ArticleId><ArticleId IdType="pubmed">21771318</ArticleId></ArticleIdList></Reference><Reference><Citation>Nijland P.G., Witte M.E., van het Hof B., van der Pol S., Bauer J., Lassmann H., van der Valk P., de Vries H.E., van Horssen J. Astroglial PGC-1alpha increases mitochondrial antioxidant capacity and suppresses inflammation: Implications for multiple sclerosis. Acta Neuropathol. Commun. 2014;2:170. doi: 10.1186/s40478-014-0170-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-014-0170-2</ArticleId><ArticleId IdType="pmc">PMC4268800</ArticleId><ArticleId IdType="pubmed">25492529</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Cruz S., Parone P.A., Lopes V.S., Lillo C., McAlonis-Downes M., Lee S.K., Vetto A.P., Petrosyan S., Marsala M., Murphy A.N., et al. Elevated PGC-1&#x3b1; Activity Sustains Mitochondrial Biogenesis and Muscle Function without Extending Survival in a Mouse Model of Inherited ALS. Cell Metab. 2012;15:778&#x2013;786. doi: 10.1016/j.cmet.2012.03.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2012.03.019</ArticleId><ArticleId IdType="pmc">PMC3565468</ArticleId><ArticleId IdType="pubmed">22560226</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney M., Pu H., Chiu A., Canto M.D., Polchow C., Alexander D., Caliendo J., Hentati A., Kwon Y., Deng H.-X., et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;1775. doi: 10.1126/science.8209258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8209258</ArticleId><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller F.L., Liu J., Jernigan A., Borchelt D., Richardson A., Van Remmen H. MnSOD deficiency has a differential effect on disease progression in two different ALS mutant mouse models. Muscle Nerve. 2008;38:1173&#x2013;1183. doi: 10.1002/mus.21049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.21049</ArticleId><ArticleId IdType="pubmed">18720509</ArticleId></ArticleIdList></Reference><Reference><Citation>Boill&#xe9;e S., Yamanaka K., Lobsiger C.S., Copeland N.G., Jenkins N.A., Kassiotis G., Cleveland D.W. Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006;312:1389&#x2013;1392. doi: 10.1126/science.1123511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1123511</ArticleId><ArticleId IdType="pubmed">16741123</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Marcos P.J., Auwerx J. Regulation of PGC-1&#x3b1;, a nodal regulator of mitochondrial biogenesis. Am. J. Clin. Nutr. 2011;93:884S&#x2013;890S. doi: 10.3945/ajcn.110.001917.</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/ajcn.110.001917</ArticleId><ArticleId IdType="pmc">PMC3057551</ArticleId><ArticleId IdType="pubmed">21289221</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Okada T., Nomoto T., Ke X., Kume A., Ozawa K., Xiao S. Promoter effects of adeno-associated viral vector for transgene expression in the cochlea in vivo. Exp. Mol. Med. 2007;39:170&#x2013;175. doi: 10.1038/emm.2007.19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emm.2007.19</ArticleId><ArticleId IdType="pubmed">17464178</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein R.L., Hamby M.E., Gong Y., Hirko A.C., Wang S., Hughes J.A., King M.A., Meyer E.M. Dose and promoter effects of adeno-associated viral vector for green fluorescent protein expression in the rat brain. Exp. Neurol. 2002;176:66&#x2013;74. doi: 10.1006/exnr.2002.7942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/exnr.2002.7942</ArticleId><ArticleId IdType="pubmed">12093083</ArticleId></ArticleIdList></Reference><Reference><Citation>Eschbach J., Schwalenst&#xf6;cker B., Soyal S.M., Bayer H., Wiesner D., Akimoto C., Nilsson A.-C., Birve A., Meyer T., Dupuis L., et al. PGC-1 is a male-specific disease modifier of human and experimental amyotrophic lateral sclerosis. Hum. Mol. Genet. 2013;22:3477&#x2013;3484. doi: 10.1093/hmg/ddt202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt202</ArticleId><ArticleId IdType="pubmed">23669350</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrera-Marcos L.V., Sancho-Knapik S., Gab&#xe1;s-Rivera C., Barranquero C., Gasc&#xf3;n S., Romanos E., Mart&#xed;nez-Beamonte R., Navarro M.A., Surra J.C., Arnal C., et al. Pgc1a is responsible for the sex differences in hepatic Cidec/Fsp27&#x3b2; mRNA expression in hepatic steatosis of mice fed a Western diet. Am. J. Physiol. Metab. 2020;318:E249&#x2013;E261. doi: 10.1152/ajpendo.00199.2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpendo.00199.2019</ArticleId><ArticleId IdType="pubmed">31846369</ArticleId></ArticleIdList></Reference><Reference><Citation>Capllonch-Amer G., Sbert-Roig M., Galmes-Pascual B.M., Proenza A.M., Llado I., Gianotti M., Garcia-Palmer F.J. Estradiol stimulates mitochondrial biogenesis and adiponectin expression in skeletal muscle. J. Endocrinol. 2014;221:391&#x2013;403. doi: 10.1530/JOE-14-0008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/JOE-14-0008</ArticleId><ArticleId IdType="pubmed">24681828</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang Z., Valenza M., Cui L., Leoni V., Jeong H.-K., Brilli E., Zhang J., Peng Q., Duan W., Reeves S.A., et al. Peroxisome-proliferator-activated receptor gamma coactivator 1 &#x3b1; contributes to dysmyelination in experimental models of Huntington&#x2019;s disease. J. Neurosci. 2011;31:9544&#x2013;9553. doi: 10.1523/JNEUROSCI.1291-11.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1291-11.2011</ArticleId><ArticleId IdType="pmc">PMC3132810</ArticleId><ArticleId IdType="pubmed">21715619</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiaei M., Kipiani K., Chen J., Calingasan N.Y., Beal M.F. Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 2005;191:331&#x2013;336. doi: 10.1016/j.expneurol.2004.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2004.10.007</ArticleId><ArticleId IdType="pubmed">15649489</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xfc;tz B., Reimann J., Dumitrescu-Ozimek L., Kappes-Horn K., Landreth G.E., Schurmann B., Zimmer A., Heneka M.T. The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J. Neurosci. 2005;25:7805&#x2013;7812. doi: 10.1523/JNEUROSCI.2038-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2038-05.2005</ArticleId><ArticleId IdType="pmc">PMC6725264</ArticleId><ArticleId IdType="pubmed">16120782</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata N., Kawaguchi-Niida M., Yamamoto T., Toi S., Hirano A., Kobayashi M. Effects of the PPAR&#x3b3; activator pioglitazone on p38 MAP kinase and I&#x3ba;B&#x3b1; in the spinal cord of a transgenic mouse model of amyotrophic lateral sclerosis. Neuropathology. 2008;28:387&#x2013;398. doi: 10.1111/j.1440-1789.2008.00890.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1789.2008.00890.x</ArticleId><ArticleId IdType="pubmed">18312546</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L., Dengler R., Heneka M.T., Meyer T., Zierz S., Kassubek J., Fischer W., Steiner F., Lindauer E., Otto M., et al. A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLoS ONE. 2012;7:e37885. doi: 10.1371/journal.pone.0037885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0037885</ArticleId><ArticleId IdType="pmc">PMC3371007</ArticleId><ArticleId IdType="pubmed">22715372</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>